Report from the 2018 Consensus Conference on Immunomodulating Agents in Thoracic Transplantation: Access, Formulations, Generics, Therapeutic Drug Monitoring, and Special Populations.

In 2009, The International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as: access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications to special populations such as pediatrics and older adults.

Source: The Journal of Heart and Lung Transplantation - July 8, 2020 Category: Transplant Surgery Authors: Adam B. Cochrane, Haifa Lyster, JoAnn Lindenfeld, Christina Doligalski, David Baran, Colleen Yost, Michael Shullo, Martin Schweiger, David Weill, Linda Stuckey, Steven Ivulich, Janet Scheel, Lisa Peters, Monica Colvin, Kyle Dawson, Reda Girgis, Phillip We Tags: Editorial Source Type: research